Dr Susan ML Lim FRCS PhD Chairman & CEO Stem Cell Technologies i

Stem Cell Technologies i (SCTi) was established by Dr Susan Lim to conduct research into Adult Stem Cells. Dr Susan Lim holds both surgical degrees and a doctorate (PhD) in basic science (transplantation immunology), and is the Chairman and Chief Executive Officer.

Stem Cell Facts

Adult tissue stem cells are robust precursors of their own tissues, but are generally unable to produce other tissues without significant experimental modification of their genetic makeup (International Society for Stem Cell Research www.isscr.org).

It takes time to confirm, understand and develop scientific breakthroughs. One of the breakthroughs is iPS cells. iPS cells are derived from adult cells but share many of the characteristics of embryonic stem cells including the ability to give rise to the cells of all organs and tissues.

It will likely be several years before we know whether iPS cells differ in clinically significant ways from human embryonic stem cells. Research in this research area is currently underway.

The focus of research at SCTi is on Ad-MSCs and its applications in regenerative medicine (fat cells, muscle cells, insulin-secreting cells and hepatocytes), cancer biology, and generation of iPS cells.

We are also studying the transfection of these cells to derive insulin-secreting cells and the use iPS technology to reprogram Ad-MSCs into the more primitive pluripotent cell type .We intend to use iPS technology for generation of insulin-secreting cells and hepatocytes.

SCTi has, as one of its projects, a joint venture with the National University of Singapore to undertake specific research into adult stem cells as cell replacement therapy for diabetes.